Hims & Hers shares jumped about 7% after announcing expanded partnership with Eli Lilly to prescribe GLP‑1 weight‑loss drugs.
The new platform lets providers send prescriptions for Zepbound vials, KwikPen and Foundayo to LillyDirect pharmacy with self‑pay pricing.
Hims & Hers’ weight‑loss membership now includes 24/7 care‑team access, personalized nutrition, clinical check‑ins and peer‑support community.
The expansion follows a prior Novo Nordisk collaboration for Wegovy access, reflecting a strategic shift in its US weight‑loss business.